The safety and efficacy of mixed liquid of etomidate and propofol in outpatients undergoing gastroscopy

The application of mixed liquid of etomidate and propofol in outpatients undergoing gastroscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14005016

Enrollment

Unknown

Registered

2014-07-21

Start date

2014-08-15

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pathological and physiological in outpatients undergoing gastroscopy

Interventions

Group P:propofol (1%, H20130504, KN520, AstraZeneca)

Group EP:mixed liquid of etomidate and propofol

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: A total of 334 ASA I to III outpatients, 18 to 60 years old, 45 to 80 kg weight, and scheduled for gastroscopy with sedation, were enrolled in the study.

Exclusion criteria

Exclusion criteria: 1. Allergic to propofol or intralipid; 2. Refused to participate in this trial or have participated in other trials; 3. Severe heart, lung, liver and kidney diseases; 4. Obstructive sleep apnea-hypopnea syndrome or BMI more than 28 kg/m2; 5. history of alcoholism or psychotropic drugs taking.

Design outcomes

Primary

Measure	Time frame
vital signs;adverse effects;	—

Countries

China

Contacts

Public ContactXiang Zhou

zhouxiang188483@126.com+86 18627718483

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026